Four RBQM case studies illustrate how our intelligent EarlyBird system forecasts future events and detects suspicious activity, to subsequently trigger on time preventive and corrective actions.
Our key risk indicator infographic will give you a foundational understanding of KRIs, provide valuable examples of KRIs, and guide you towards getting started with your risk-based monitoring (RBM) program.
Die Fachtagungen des DVMD sind jedes Mal ein informativer Querschnitt aus allen relevanten Themen rund um Dokumentation und Informationsmanagement in der Medizin. Jede Fachtagung greift dabei immer ein Schwerpunktthema auf. In 2019 wird es der Einfluss der Digitalisierung auf die Medizin sein.
Sponsor, Speaker....and Many New Features to Demo With a surge of new technologies and trial models being implemented, the time is now to capitalise on industry expertise to capture the cost and efficiency benefits of risk-based monitoring. Join us in London for CBI’s 3rd annual Global [...]
The dramatic expansion of prescription drug deaths inspired this year's theme "driving insights to action". Insights that could be deployed through novel disruptive technologies such as Risk-based Quality Management (RBQM). Cyntegrity's Johann Proeve and Nimita Limaye were in Boston and share their observations with us.
By design, the traditional spot-checking type of audits leave a blind spot on systemic quality threats. Key Risk Indicators however, form the core of a widely applicable concept that captures all relevant risks in scope and provides project managers and QM experts targeted and objective updates on actionable issues and trends.
J. Proeve, Ph.D., an expert with 35+ years of experience as Global Data Management Head at Bayer started this week as Chief Scientific Officer at Cyntegrity. He takes the responsibility of building up a proper Risk-based Monitoring (RBM) strategy for each clinical study and develop further Cyntegrity's core product RBM [...]
The majority of companies are delaying the RBM adoption. Why? The reason lies now in the nature of innovation adoption. The main hesitations of the pragmatists to apply RBM nowadays are connected with: the general complexity of the approach the perceived risk of audit findings [...]
Interview with Artem Andrianov during PCT 2015: What Pharma Gains from Structured RBM?